LZI ORAL FLUID AMPHETAMINE ENZYME IMMUNOASSAY, CALIBRATORS, CONTROLS

K131653 · Lin-Zhi International, Inc. · DKZ · Feb 4, 2014 · Clinical Toxicology

Device Facts

• Record ID: K131653
• Device Name: LZI ORAL FLUID AMPHETAMINE ENZYME IMMUNOASSAY, CALIBRATORS, CONTROLS
• Applicant: Lin-Zhi International, Inc.
• Product Code: DKZ · Clinical Toxicology
• Decision Date: Feb 4, 2014
• Decision: SESE
• Submission Type: Traditional
• Regulation: 21 CFR 862.3100
• Device Class: Class 2

Indications for Use

The LZI Oral Fluid Amphetamine Enzyme Immunoassay is intended for the qualitative determination of d-amphetamine in neat human oral fluid, collected into the LZI Oral Fluid Collector, at the cutoff value of 50 ng/mL. The assay is designed for prescription use with a number of automated clinical chemistry analyzers. The semi-quantitative mode is for purposes of (1) enabling laboratories to determine an appropriate dilution of the specimen for confirmation by a confirmatory method such as GCMS or (2) permitting laboratories to establish quality control procedures. The LZI Oral Fluid Amphetamine Calibrators are for use as calibrators in the qualitative calibration of the LZI Oral Fluid Amphetamine Enzyme Immunoassay at the cutoff value of 50 ng/mL. The LZI Oral Fluid Amphetamine Controls are for use as assayed quality control materials to monitor the LZI Oral Fluid Amphetamine Enzyme Immunoassay at the cutoff value of 50 ng/mL. The assay provides only a preliminary analytical result. A more specific alternative chemical method must be used in order to obtain a confirmed analytical result. Gas or liquid chromatography/mass spectrometry (GCMS) is the preferred confirmatory method. Clinical consideration and professional judgment should be exercised with any drug of abuse test result, particularly when the preliminary test result is positive.

Device Story

Homogeneous enzyme immunoassay for d-amphetamine detection in neat oral fluid; utilizes competition between sample drug and G6PDH-labeled drug for fixed antibody binding sites. Enzyme activity inversely proportional to drug concentration; active enzyme converts NAD to NADH, measured spectrophotometrically at 340 nm. Used in clinical laboratories by professional staff on automated chemistry analyzers. Provides preliminary screening results; requires confirmatory testing via GC/MS or LC/MS. Aids clinical decision-making regarding drug use; supports laboratory quality control and specimen dilution for confirmation.

Clinical Evidence

Bench testing only. Precision evaluated over 22 days (n=88) showing consistent qualitative/semi-quantitative results. Linearity/recovery tested across 0-140 ng/mL range. Analytical specificity tested against endogenous/exogenous interferents and structurally related/unrelated drugs; no interference observed. Method comparison performed on 85 clinical samples against LC/MS, demonstrating 97.7% positive agreement and 100% negative agreement.

Technological Characteristics

Homogeneous enzyme immunoassay; reagents contain mouse monoclonal anti-amphetamine antibody, G6PDH-labeled amphetamine, G6P, and NAD. Matrix: neat oral fluid. Detection: spectrophotometric (340 nm). Storage: 2-8°C. Connectivity: compatible with automated clinical chemistry analyzers. Collection: 50 mL polypropylene tube.

Indications for Use

Indicated for qualitative and semi-quantitative determination of d-amphetamine in neat human oral fluid for prescription use in clinical settings to aid in drug of abuse testing.

Regulatory Classification

Identification

An amphetamine test system is a device intended to measure amphetamine, a central nervous system stimulating drug, in plasma and urine. Measurements obtained by this device are used in the diagnosis and treatment of amphetamine use or overdose and in monitoring levels of amphetamine to ensure appropriate therapy.

Special Controls

*Classification.* Class II (special controls). An amphetamine test system is not exempt if it is intended for any use other than employment or insurance testing or is intended for Federal drug testing programs. The device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 862.9, provided the test system is intended for employment and insurance testing and includes a statement in the labeling that the device is intended solely for use in employment and insurance testing, and does not include devices intended for Federal drug testing programs (*e.g.,* programs run by the Substance Abuse and Mental Health Services Administration (SAMHSA), the Department of Transportation (DOT), and the U.S. military).

Predicate Devices

• LZI Oral Fluid Amphetamine-Specific Enzyme Immunoassay (k063024)
• LZI Oral Fluid Amphetamine Metabolite Calibrators (k063024)
• LZI Oral Fluid Amphetamine Metabolite Controls (k063024)

Submission Summary (Full Text)

{0}

1

510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION
DECISION SUMMARY
ASSAY ONLY TEMPLATE

A. 510(k) Number:
k131653

B. Purpose for Submission:
Modification of cut-off value from a previously cleared assay

C. Measurand:
Amphetamine

D. Type of Test:
Qualitative and Semi-Quantitative Enzyme Immunoassay

E. Applicant:
Lin-Zhi International, Inc.

F. Proprietary and Established Names:
LZI Oral Fluid Amphetamine Enzyme Immunoassay
LZI Oral Fluid Amphetamine Calibrators
LZI Oral Fluid Amphetamine Controls

G. Regulatory Information:

1. Regulation section:
21 CFR 862.3100, Amphetamine test system
21 CFR 862.3200, Clinical toxicology calibrator
21 CFR 862.3280, Clinical toxicology control material

2. Classification:
Class II (test system, calibrator)
Class I, reserved (control material)

3. Product code:
DKZ, enzyme immunoassay, amphetamine

{1}

DLJ, calibrators, drug specific
LAS, drug specific control materials

4. Panel:
Toxicology (91)

H. Intended Use:

1. Intended use(s):
See indications for use below.

2. Indication(s) for use:
The LZI Oral Fluid Amphetamine Enzyme Immunoassay is intended for the qualitative and semi-quantitative determination of d-amphetamine in neat human oral fluid, collected into the LZI Oral Fluid Collector at the cutoff value of 50 ng/mL. The assay is designed for prescription use with a number of automated clinical chemistry analyzers.

The semi-quantitative mode is for purposes of (1) enabling laboratories to determine an appropriate dilution of the specimen for confirmation by a confirmatory method such as GCMS and LCMS or (2) permitting laboratories to establish quality control procedures.

The LZI Oral Fluid Amphetamine Calibrators are for use as calibrators in the qualitative and semi-quantitative calibration of the LZI Oral Fluid Amphetamine Enzyme Immunoassay at the cutoff value of 50 ng/mL.

The LZI Oral Fluid Amphetamine Controls are for use as assayed quality control materials to monitor the precision of the LZI Oral Fluid Amphetamine Enzyme Immunoassay at the cutoff value of 50 ng/mL.

The assay provides only a preliminary analytical result. A more specific alternative chemical method must be used in order to obtain a confirmed analytical result. Gas or liquid chromatography/mass spectrometry (GC/MS or LC/MS) is the preferred confirmatory method). Clinical consideration and professional judgment should be exercised with any drug of abuse test result, particularly when the preliminary test result is positive.

3. Special conditions for use statement(s):
For prescription use only.

4. Special instrument requirements:
The assay is designed for prescription use with a number of clinical chemistry analyzers. Performance data was obtained using the Hitachi 717 analyzer.

2

{2}

I. Device Description:

The LZI Oral Fluid Amphetamine Enzyme Immunoassay is a kit comprised of two reagents, which are bottled separately but sold together within the kit. Reagent 1 contains mouse monoclonal anti-amphetamine antibody, glucose-6-phosphate (G6P) nicotinamide adenine dinucleotide (NAD), stabilizers, and sodium azide (0.09%) as a preservative. Reagent 2 contains glucose-6-phosphate dehydrogenase (G6PDH) labeled with amphetamine in buffer with sodium azide (0.09%) as a preservative. Oral fluid is collected into the LZI Oral Fluid Collector, which consists of a 50 mL Polypropylene Tube.

The LZI Oral Fluid Amphetamine Enzyme Immunoassay calibrators and controls, sold as individual bottles, are designated for use at the 50 ng/mL cutoffs. Calibrators contain 0, 25, 50, 100, and 140 ng/mL of amphetamine in human oral fluid with sodium azide (0.09%) as preservative. Controls contain levels of 37.5, and 62.5 ng/mL in the same matrix.

J. Substantial Equivalence Information:

1. Predicate device name(s):

LZI Oral Fluid Amphetamine-Specific Enzyme Immunoassay
LZI Oral Fluid Amphetamine Metabolite Calibrators
LZI Oral Fluid Amphetamine Metabolite Controls

2. Predicate 510(k) number(s):

k063024

3. Comparison with predicate:

| Similarities | | |
| --- | --- | --- |
| Item | New Device | Predicate |
| Intended Use | For use in the detection of amphetamine in human oral fluid. | Same |
| Methodology | Enzyme immunoassay | Same |
| Matrix | Oral Fluid | Same |
| Analyte | Amphetamine | Same |
| Storage | 2-8°C until expiration date | Same |
| Differences | | |
| --- | --- | --- |
| Item | New Device | Predicate |
| Cut-off | 50 ng/mL | 45 ng/mL |
| Measurement Mode | Qualitative and semi-quantitative | Qualitative |
| Calibrators | Four levels (20, 50, 100, 140 ng/mL | Two levels (15 and 45 ng/mL |

{3}

4

| Differences | | |
| --- | --- | --- |
| Item | New Device | Predicate |
| Controls | Two levels (37.5 and 62.5 ng/mL) | Two levels (15 and 45 ng/mL) |

K. Standard/Guidance Document Referenced (if applicable):

EP5-A2: Evaluation of Precision Performance of Clinical Chemistry Devices.

L. Test Principle:

The assay is based on competition between drug in the sample and drug labeled with the enzyme glucose-6-phosphate dehydrogenase (G6PDH) for a fixed amount of antibody in the reagent. Enzyme activity decreases upon binding to the antibody, and the drug concentration in the sample is measured in terms of enzyme activity. In the absence of drug in the sample, amphetamine-labeled G6PDH conjugate is bound to antibody, and the enzyme activity is inhibited. On the other hand, when free drug is present in the sample, antibody would bind to free drug and the unbound Amphetamine-labeled G6PDH exhibits its maximal enzyme activity. Active enzyme converts nicotinamide adenine dinucleotide (NAD) to NADH, resulting in an absorbance change that can be measured spectrophotometrically at 340 nm.

M. Performance Characteristics (if/when applicable):

1. Analytical performance:

a. Precision/Reproducibility:

Precision of the qualitative and semi-quantitative assays was evaluated by testing a single lot of calibrator and control material on the Hitachi 717 analyzer. A primary stock solution of d-amphetamine (1000 ng/mL) was diluted into negative synthetic oral fluid matrix to obtain the target concentrations shown below. Samples were tested in replicates of 2, twice a day for 22 days (total n=88). A summary of the results for each cut-off values for qualitative and semi-quantitative modes are shown below:

Qualitative Mode

| 50 ng/mL Cutoff | | Within Run | | Total Precision | |
| --- | --- | --- | --- | --- | --- |
| Sample Concentration (ng/mL) | % of Cutoff | Number of Determinations | Immunoassay Result | Number of Determinations | Immunoassay Result |
| 0 | -100.0 | 22 | 22 Negative | 88 | 88 Negative |
| 12.5 | -75.0 | 22 | 22 Negative | 88 | 88 Negative |
| 25 | -50.0 | 22 | 22 Negative | 88 | 88 Negative |
| 37.5 | -25.0 | 22 | 22 Negative | 88 | 88 Negative |

{4}

5

| 50 | 0 | 22 | 8 Pos/ 14 Neg | 88 | 46 Pos/ 42 Neg |
| --- | --- | --- | --- | --- | --- |
| 62.5 | +25.0 | 22 | 22 Positive | 88 | 88 Positive |
| 75 | +50.0 | 22 | 22 Positive | 88 | 88 Positive |
| 87.5 | +75.0 | 22 | 22 Positive | 88 | 88 Positive |
| 100 | +100.0 | 22 | 22 Positive | 88 | 88 Positive |

## Semi-Quantitative Mode

| 50 ng/mL Cutoff | | Within Run | | Total Precision | |
| --- | --- | --- | --- | --- | --- |
| Sample Concentration (ng/mL) | % of Cutoff | Number of Determinations | Immunoassay Result | Number of Determinations | Immunoassay Result |
| 0 | -100.0 | 22 | 22 Negative | 88 | 88 Negative |
| 12.5 | -75.0 | 22 | 22 Negative | 88 | 88 Negative |
| 25 | -50.0 | 22 | 22 Negative | 88 | 88 Negative |
| 37.5 | -25.0 | 22 | 22 Negative | 88 | 88 Negative |
| 50 | 0 | 22 | 11 Pos/ 11 Neg | 88 | 36 Pos/ 52 Neg |
| 62.5 | +25.0 | 22 | 22 Positive | 88 | 88 Positive |
| 75 | +50.0 | 22 | 22 Positive | 88 | 88 Positive |
| 87.5 | +75.0 | 22 | 22 Positive | 88 | 88 Positive |
| 100 | +100.0 | 22 | 22 Positive | 88 | 88 Positive |

## b. Linearity/assay reportable range:

Linearity and % recovery across the range was tested by spiking a commercially available amphetamine standard into negative synthetic oral fluid. The high concentration was diluted to reach the final concentrations (expected values) listed below. Each sample was run in 10 replicates on the Hitachi 717 clinical analyzer in semi-quantitative mode with a calibration curve established with the 5 Oral Fluid Amphetamine calibrators (0, 25, 50, 100, 140 ng/mL). The average results were compared to the expected results and percent recovery was calculated.

| Expected Value (ng/mL) | Observed Value (ng/mL) | % Recovery |
| --- | --- | --- |
| 140 | 141.72 | 101.2 |
| 120 | 134.26 | 111.9 |
| 100 | 104.69 | 104.7 |
| 80 | 80.98 | 101.2 |
| 60 | 60.72 | 101.2 |
| 50 | 53.10 | 106.2 |
| 40 | 42.36 | 105.9 |

{5}

| 30 | 30.89 | 103.0 |
| --- | --- | --- |
| 20 | 18.80 | 94.0 |
| 0 | 0.16 | N/A |

c. Traceability, Stability, Expected values (controls, calibrators, or methods):

## Traceability

The starting material for calibrators and controls is a commercially available amphetamine stock solution of 1000 µg/mL. Purity determination (99% purity) and and gravimetric preparation was performed using balances calibrated with NIST traceable weights.

## Value Assignment

A secondary stock solution of 10 µg/mL (made from the commercially available standard noted above) was spiked into the synthetic negative oral fluid to the desired concentration for calibrators and controls. The resulting concentrations were confirmed by LC/MS.

## Stability

Real time studies have been conducted over 18 months for calibrators and controls stored at 2-8 °C. Samples stored at 2-8 °C over 18 months were compared to samples measured on Day 1. Protocols and acceptance criteria in the 510(k) were reviewed and found to be acceptable. Data in the 510(k) support the sponsor’s claimed 18 months expiration dating for both open vial and closed vial stability at 2 °C to 8 °C.

## Shipping/Recovery Study

A shipping study was performed to demonstrate the recovery of drug from oral fluid when collected in the LZI Oral Fluid Collector collection tube (provided for confirmation testing) by testing expected transport conditions. Conditions simulating transport to 3 different destination sites with varied weather conditions (-20 °C, 2-8°C, room temperature and 30°C) were performed. Four sets of pooled negative oral fluid samples (25 mL each) were spiked with d-amphetamine into glass flasks to 50%, 75%, 125% and 150% of the cutoff concentration. These samples served as pre-shipping controls for analyte recovery (Day 1). The samples at each concentration were then pipetted (4.5 mL) into individual LZI Oral Fluid Collectors and kept at one of the 4 storage temperatures over 3 days. After 72 hours, all 16 samples were brought to room temperature and tested with LZI Oral Fluid Amphetamine Enzyme Immunoassay. One mL of each of the 16 samples were transferred into amber glass vials and shipped with gel ice overnight for GC/MS confirmation.

A total of 20 samples were evaluated, consisting of 16 post-shipping and 4 pre-shipping controls. The samples consisting of 4 concentrations stored at 4 temperature conditions on the 4th day did not show any degradation when compared to counterpart samples (Day 1), with sample recoveries ranging from 99.2% to 100.1% for all cutoff concentrations tested. Sample recoveries compared to GC/MS are show below:

{6}

| Target d-amphetamine Concentration (ng/mL) | % of Cutoff Concentration | Shipping Condition | Average GC/MS Concentration (ng/mL) | % Recovery compared to Pre-ship |
| --- | --- | --- | --- | --- |
| 25 | -50 | Pre-Ship (Control) | 27.5 | 100 |
| | | Frozen (-20°C) | 27 | 98.4 |
| | | Cold | 27.7 | 100.7 |
| | | Room Temp. | 27.4 | 99.6 |
| | | 30°C | 27.8 | 101.3 |
| 37.5 | -25 | Pre-Ship (Control) | 42 | 100 |
| | | Frozen (-20°C) | 41.7 | 99.3 |
| | | Cold | 41.6 | 99.2 |
| | | Room Temp. | 39.8 | 94.9 |
| | | 30°C | 43.8 | 104.3 |
| 62.5 | 25 | Pre-Ship (Control) | 69.3 | 100 |
| | | Frozen (-20°C) | 69.6 | 100.4 |
| | | Cold | 70.2 | 101.3 |
| | | Room Temp. | 69.7 | 100.6 |
| | | 30°C | 69 | 99.6 |
| 75 | 50 | Pre-Ship (Control) | 84 | 100 |
| | | Frozen (-20°C) | 79.1 | 94.2 |
| | | Cold | 80.1 | 95.4 |
| | | Room Temp. | 82.6 | 98.3 |
| | | 30°C | 85.6 | 101.8 |

## Sample Storage and Stability:

Real time and accelerated stability studies have been conducted for sample storage for various conditions (frozen, room temperature, refrigerated and 30 °C). Real time stability studies are ongoing. Protocols and acceptance criteria were described and found to be acceptable. The manufacturer claims that d-amphetamine (AMP) saliva samples may be stored in the LZI Oral Fluid Collectors (polypropylene collection tubes) up to two weeks when stored at 2-8 °C, or up to 24 months when stored at -20 °C.

d. Detection limit:

Not applicable.

e. Analytical specificity:

The potential effect of endogenous and exogenous interferents at physiologically

{7}

relevant concentrations was tested by spiking the interferents into synthetic negative oral fluid to the desired concentrations (shown below). A portion of the oral fluid containing the interferents was then spiked with a concentration of 37.5 ng/mL d-amphetamine (-25% cut-off) or 62.5% ng/mL d-amphetamine (+25% cut-off). No interference was observed. The substances tested and concentrations are shown below:

Endogenous Compounds

| Interfering Substance | Spiked Concentration (mg/mL) |
| --- | --- |
| Ascorbic Acid | 10 |
| Bilirubin | 0.05 |
| Cholesterol | 0.45 |
| Cotinine | 0.01 |
| γ-globulin | 0.8 |
| Hemoglobin | 0.6 |
| HAS | 5 |
| Nicotine | 0.03 |
| Sodium Chloride | 18 |
| pH 3 | n/a |
| pH 4 | n/a |
| pH 5 | n/a |
| pH 6 | n/a |
| pH 7 | n/a |
| pH 8 | n/a |
| pH 9 | n/a |
| pH 10 | n/a |

Exogenous Compounds

| Interfering Substance | Concentration of Compound (% V/V) |
| --- | --- |
| Alcohol (Ethanol) | 5 |
| Coffee | 5 |
| Cough Syrup | 5 |
| Cranberry Juice | 5 |
| Sugar | 50 mg/mL |
| Milk | 5 |
| Mouthwash | 5 |
| Orange Juice | 5 |
| Soft Drink (Coke) | 5 |
| Tea | 5 |
| Toothpaste | 5 |
| Water | 5 |

{8}

Cross-reactivity of structurally related drugs was tested by spiking various concentrations of each substance into drug free synthetic oral fluid and evaluated against the assay's calibrated dose-response curve. The concentrations shown in the table below for each compound had to be equivalent to $\pm 25\%$ in assay reactivity to the $50~\mathrm{ng/mL}$ amphetamine cut-off. The $\%$ cross-reactivity results are shown below:

| Compound | Concentration (ng/mL) of compound yielding result equivalent to 50 ng/mL d-amphetamine | % Cross-reactivity |
| --- | --- | --- |
| d-amphetamine | 50 | 100.06 |
| l-amphetamine | 3,000 | 1.42 |
| Dimethylamylamine(DMAA) | 100,000 | 0.05 |
| d-Ephedrine | 300,000 | 0.00 |
| d,l-Ephedrine | 300,000 | 0.00 |
| l-Ephedrine | 200,000 | 0.00 |
| Fenfluramine | 200,000 | 0.02 |
| 3-Hydroxy-Tyramine | 200,000 | 0.01 |
| Isoxsuprine | 250,000 | 0.00 |
| MDA(methylenedioxyamphetamine) | 150 | 27.40 |
| MDMA(methylenedioxymethamphetamine) | 10,000 | 0.05 |
| Mephentermine | 100,000 | 0.02 |
| d-Methamphetamine | 10,000 | 0.04 |
| l-Methamphetamine | 50,000 | 0.00 |
| Phendimetrazine | 100,000 | 0.00 |
| Phenethylamine | 10,000 | 0.46 |
| Phenmetrazine | 100,000 | 0.03 |
| Phentermine | 2,000 | 1.60 |
| d,l-Phenylpropanolamine | 20,000 | 0.19 |
| PMA(para-Methoxyamphetamine) | 500 | 7.62 |
| d-Pseudoephedrine | 250,000 | 0.00 |
| l-Pseudoephedrine | 250,000 | 0.00 |

Structurally unrelated drugs were evaluated by spiking the primary stock solutions into synthetic negative oral fluid to the concentrations listed below. A secondary stock solution of d-amphetamine was spiked into the oral fluid containing the interferent to a concentration of $37.5~\mathrm{ng/mL}$ d-amphetamine ($-25\%$ cut-off) or $62.5\%$

{9}

ng/mL d-amphetamine (+25% cut-off). No positive or negative interference was observed from the compounds at the concentrations shown below.

| Compound | Target Concentration (ng/mL) |
| --- | --- |
| Acetaminophen | 60,000 |
| Acetylsalicylic acid | 60,000 |
| Amobarbital | 60,000 |
| Benzoylecgonine | 60,000 |
| Bromopheniramine | 50,000 |
| Bupropion | 15,000 |
| Buspiron | 20,000 |
| Caffeine | 60,000 |
| Chlorpheniramine | 20,000 |
| Chlorpromazine | 20,000 |
| Codeine | 50,000 |
| Dextromethorphan | 60,000 |
| Doxepine | 15,000 |
| Meperidine | 60,000 |
| Methadone | 50,000 |
| Methapyrilene | 15,000 |
| Methaqualone | 15,000 |
| Morphine | 50,000 |
| Oxazepam | 50,000 |
| Phencyclidine | 50,000 |
| Phenobarbital | 50,000 |
| Phenothiazine | 50,000 |
| Procainamide | 60,000 |
| Promethazine | 20,000 |
| Propoxyphene | 60,000 |
| Propranolol | 60,000 |
| Ranitidine | 60,000 |
| Scopolamine | 60,000 |
| Secobarbital | 60,000 |
| Sertraline | 15,000 |
| Thioridazine | 60,000 |
| Trazodone | 60,000 |
| Trifluoperazine | 20,000 |
| Trifluopromazine | 20,000 |
| Valproic Acid | 60,000 |

{10}

f. Assay cut-off:

Characterization of how the device performs analytically around the claimed cut-off concentration appears in the precision/reproducibility section above.

2. Comparison studies:

a. Method comparison with predicate device:

Eighty-five unaltered clinical samples collected in the LZI Oral Fluid Collector were tested using the LZI Oral Fluid Amphetamine Enzyme Immunoassay on the Hitachi 717 automated clinical analyzers and confirmed with LC/MS for d-amphetamine concentration. Results obtained in the qualitative mode and semi-quantitative mode are summarized below:

Qualitative

| 50 ng/mL Cut-off | Negative | < 50% of the cut-off | Near cut-off (between 50% below the cut-off and the cut-off) | Near cut-off positive (concentration between 50% above the cut-off and the cut-off) | > 50% above the cut-off | % Agreement |
| --- | --- | --- | --- | --- | --- | --- |
| Positive | 0 | 0 | 0 | 10 | 32 | 97.7% |
| Negative | 22 | 11 | 9 | 1* | 0 | 100.0% |

Semi-Quantitative

| 50 ng/mL Cut-off | Negative | < 50% of the cut-off | Near cut-off (between 50% below the cut-off and the cut-off) | Near cut-off positive (concentration between 50% above the cut-off and the cut-off) | > 50% above the cut-off | % Agreement |
| --- | --- | --- | --- | --- | --- | --- |
| Positive | 0 | 0 | 0 | 10 | 32 | 97.7% |
| Negative | 22 | 11 | 9 | 1* | 0 | 100.0% |

*The discordant sample contained 63 ng/mL by the mass spectrometry method and 45.7 ng/mL by LZI Oral Fluid Amphetamine Enzyme Immunoassay on the Hitachi 717.

b. Matrix comparison:

Not applicable.

{11}

3. Clinical studies:
a. Clinical Sensitivity:
Not applicable.
b. Clinical specificity:
Not applicable.
c. Other clinical supportive data (when a. and b. are not applicable):
Not applicable.

4. Clinical cut-off:
Not applicable.

5. Expected values/Reference range:
Not applicable.

N. Proposed Labeling:
The labeling is sufficient and it satisfies the requirements of 21 CFR Part 809.10.

O. Conclusion:
The submitted information in this premarket notification is complete and supports a substantial equivalence decision.

12